Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.82, up 2.14% on the session, giving a market capitalisation of $82.3M. On trailing twelve-month figures it carries a trailing P/E of -3.39, a net margin of 0.0%. Its beta of 1.14 implies it has historically moved more than the broad market.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc. is most often compared with the following Healthcare names: